Margaret McGrath

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial

Jean‐Pascal Machiels, Yungan Tao, Lisa Licitra et al. · The Lancet Oncology · 2024 · 174 citations · Full text

Concurrent Chemoradiotherapy, Neoadjuvant Therapy, Squamous Cell Carcinoma +6

Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma

Matthew Foote, Margaret McGrath, Alexander Guminski et al. · Annals of Oncology · 2014 · 159 citations · Full text

Medicine, Single-agent Panitumumab, Pathology +8

Randomized Trial of Radiation Therapy With Weekly Cisplatin or Cetuximab in Low-Risk HPV-Associated Oropharyngeal Cancer (TROG 12.01) – A Trans-Tasman Radiation Oncology Group Study

Danny Rischin, Madeleine King, Liz Kenny et al. · International Journal of Radiation Oncology*Biology*Physics · 2021 · 133 citations

Weekly Cisplatin, Radiation Medicine, Oncology +6

Progress in diffuse intrinsic pontine glioma: advocating for stereotactic biopsy in the standard of care

John R. Williams, Christopher C. Young, Nicholas A. Vitanza et al. · Neurosurgical FOCUS · 2020 · 75 citations · Full text

Pediatric Brain Tumors, Pediatric Brainstem Biopsy, Pathology +27